

Name of Journal: *World Journal of Virology*

Manuscript NO: 59595

Manuscript Type: REVIEW

Emerging Therapeutics in the Management of COVID-19

COVID-19 Therapeutics

Abstract

Background: The SARS-CoV-2 (COVID-19) pandemic has placed a tremendous burden on healthcare systems globally. Therapeutics for treatment of the virus are extremely inconsistent due to the lack of time evaluating drug efficacy in clinical trials. Currently, there is a deficiency of published literature that comprehensively discusses all therapeutics being considered for the treatment of COVID-19.

Methods: A review of the literature was performed for articles related to therapeutics and clinical trials in the context of the current COVID-19 pandemic. We used PubMed, Google Scholar, and Clinicaltrials.gov to search for articles relative to the topic of

Match Overview

1	Internet 200 words crawled on 28-Sep-2020 moitessier-group.mcgill.ca	2%
2	Crossref 183 words Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Mi sra. "Remdesivir in COVID-19: A critical review of pharma...	1%
3	Internet 171 words www.ncbi.nlm.nih.gov	1%
4	Internet 99 words crawled on 27-Nov-2020 www.mysciencework.com	1%
5	Internet 91 words crawled on 24-Jun-2020 www.nejm.org	1%
6	Internet 72 words crawled on 10-May-2020 www.jbc.org	1%
7	Crossref 53 words Arghadip Samaddar, Malika Grover, Vijaya Lakshmi Nag. "Pathophysiology and Potential Therapeutic Candidates f...	<1%
8	Internet 46 words crawled on 02-Jul-2020 www.ashp.org	<1%

ALL

IMAGES

VIDEOS

108,000,000 Results

Any time ▾

Emerging therapeutics for the management of COVID 19

<https://pubmed.ncbi.nlm.nih.gov/32799566>

Emerging therapeutics for the management of COVID 19 The development of novel molecules and vaccines has been a challenge during this urgent crisis. **Nucleoside analogues** and **IL-6 receptor antagonists** have been identified as the best candidates for treatment of this disease.

Author: Sujit Kumar Debnath, Rohit Srivastava, ... **Publish Year:** 2020

Therapeutic Management | COVID-19 Treatment Guidelines

<https://www.covid19treatmentguidelines.nih.gov/therapeutic-management> ▾

Oct 09, 2020 · A number of investigational agents and drugs that are approved for other indications are currently being studied in clinical trials for the **treatment of COVID-19** and associated complications.

Data from randomized controlled trials, prospective and retrospective observational cohorts, and case series studies are rapidly **emerging**. The **COVID-19 Treatment Guidelines Panel** (the Panel) continues ...

BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment ...

<https://www.globenewswire.com/news-release/2020/11/...> ▾

Nov 16, 2020 · BioAegis' Phase 2 clinical trial of recombinant human plasma gelsolin (rhu-pGSN) for the treatment of severe **COVID-19** was initiated in August in Spain where **COVID-19** cases were spiking.

Search Tools

Turn on Hover Translation (开启取词)

激活 Windows

转到“设置”以激活 Windows。

Emerging Therapeutics in the Management of COVID-19



ALL

IMAGES

VIDEOS

94,800,000 Results

Any time ▼

Emerging therapeutics for the management of COVID 19

<https://pubmed.ncbi.nlm.nih.gov/32799566>

Emerging therapeutics for the management of COVID 19 The development of novel molecules and vaccines has been a challenge during this urgent crisis. **Nucleoside analogues** and **IL-6 receptor antagonists** have been identified as the best candidates for treatment of this disease.

Author: Sujit Kumar Debnath, Rohit Srivastava, ... **Publish Year:** 2020

Therapeutic Management | COVID-19 Treatment Guidelines

<https://www.covid19treatmentguidelines.nih.gov/therapeutic-management> ▼

Dec 03, 2020 · There are insufficient data for the Panel to recommend either for or against the use of remdesivir for the treatment of COVID-19. The Panel recommends against the use of **dexamethasone** (AI) or other corticosteroids for the treatment of COVID-19 (AIII) unless a patient has another clinical indication for **corticosteroid therapy**.

What is the impact of COVID-19 pandemic upon therapeutics ...

[https://www.aacc.org/science-and-research/...](https://www.aacc.org/science-and-research/) ▼

Dec 01, 2020 · When **COVID-19** struck, the U.S. was already in the grip of the drug-overdose crisis, and unfortunately it has gotten worse during these unprecedented times. Counties in states spanning the country, from Washington to Arizona and Florida, are reporting rising drug fatalities this year, according to data collected by The Wall Street Journal (5).

More Than 500 Therapeutics Being Investigated for COVID-19

<https://www.pharmacytimes.com/interviews/more-than...> ▼

Nov 18, 2020 · **Remdesivir** (**Veklury**, Gilead Sciences) was the first drug approved in the United States, indicated for hospitalized patients with COVID-19. **Haydock** said trials showed a reduction in recovery



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

95,200,000 Results

Any time ▾

Emerging therapeutics for the management of COVID 19

<https://pubmed.ncbi.nlm.nih.gov/32799566>

Emerging therapeutics for the management of COVID 19 The development of novel molecules and vaccines has been a challenge during this urgent crisis. **Nucleoside analogues** and **IL-6 receptor antagonists** have been identified as the best candidates for treatment of this disease.

Author: Sujit Kumar Debnath, Rohit Srivastava, ... **Publish Year:** 2020

Therapeutic Management | COVID-19 Treatment Guidelines

<https://www.covid19treatmentguidelines.nih.gov/therapeutic-management> ▾

Dec 03, 2020 · There are insufficient data for the Panel to recommend either for or against the use of remdesivir for the treatment of COVID-19. The Panel recommends against the use of **dexamethasone** (AI) or other corticosteroids for the treatment of COVID-19 (AIII) unless a patient has another clinical indication for **corticosteroid therapy**.

COVID-19 Therapeutics Prioritized for Testing in Clinical ...

<https://www.nih.gov/research-training/medical...> ▾

Dec 04, 2020 · Working in an unprecedented timeframe, the ACTIV public-private partnership has evaluated hundreds of available **therapeutic** agents with potential application for **COVID-19**, prioritized the most promising candidates, designed and harmonized **five adaptive master protocols** for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized **therapeutic** ...

More Than 500 Therapeutics Being Investigated for COVID-19

<https://www.pharmacytimes.com/interviews/more-than...> ▾

Nov 18, 2020 · **Remdesivir** (**Veklury**, Gilead Sciences) was the first drug approved in the United States, indicated for hospitalized patients with COVID-19. **Haydock** said trials showed a reduction in recovery time and a slight mortality benefit, though it was not statistically significant.